Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study

OBJECTIVES: Bimekizumab, a dual interleukin (IL)-17A/IL-17F inhibitor, has demonstrated clinical efficacy in clinical trials. However, real-world evidence comparing outcomes according to previous biologic exposure remains limited. We evaluated the effectiveness of bimekizumab in biologic-naïve and biologic-experienced patients with plaque psoriasis, including high-impact body areas. METHODS: We retrospectively analyzed 98 patients treated with bimekizumab (23 biologic-naïve, 75 biologic-experienced). Outcomes included Psoriasis Area and Severity Index (PASI), PASI90 and PASI100 response rates, and Physician Global Assessment (PGA) scores for scalp, nail, genital, palmoplantar, and pretibial psoriasis. Biologic-experienced patients were further stratified by the number of prior biologics. Similar findings were observed in high-impact areas. Differences persisted through week 16 but disappeared from week 24 onward. Nevertheless, biologic-naïve patients maintained numerically higher response rates throughout follow-up. Previous biologic burden did not compromise long-term outcomes. CONCLUSIONS: Bimekizumab showed sustained effectiveness regardless of prior biologic exposure. Nevertheless, biologic-naïve patients achieved faster and deeper responses, supporting earlier use of bimekizumab to maximize treatment benefit.